Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD)

Dawid Piecuch, Edyta Hanczyk, Katarzyna Zemsta, Michał Zwoliński, Szymon Kopciał, Joanna Jońska

Open source

DOI
10.3390/diagnostics15172243
Published
2025-09-04
Container
Diagnostics
Publisher
MDPI AG
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3390/diagnostics15172243,
  title = {Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD)},
  author = {Dawid Piecuch and Edyta Hanczyk and Katarzyna Zemsta and Michał Zwoliński and Szymon Kopciał and Joanna Jońska},
  year = {2025},
  journal = {Diagnostics},
  doi = {10.3390/diagnostics15172243},
  url = {https://doi.org/10.3390/diagnostics15172243}
}

RIS

TY  - JOUR
TI  - Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD)
AU  - Dawid Piecuch
AU  - Edyta Hanczyk
AU  - Katarzyna Zemsta
AU  - Michał Zwoliński
AU  - Szymon Kopciał
AU  - Joanna Jońska
PY  - 2025
JO  - Diagnostics
DO  - 10.3390/diagnostics15172243
UR  - https://doi.org/10.3390/diagnostics15172243
ER  - 

APA

Piecuch, D., Hanczyk, E., Zemsta, K., Zwoliński, M., Kopciał, S., & Jońska, J. (2025). Diagnostics, Efficacy, and Safety of Immunomodulatory and Anti-Fibrotic Treatment for Interstitial Lung Disease Associated with Systemic Scleroderma (SSc-ILD). Diagnostics. https://doi.org/10.3390/diagnostics15172243

Source records